Back to top
more

Black Diamond Therapeutics (BDTX)

(Delayed Data from NSDQ)

$5.89 USD

5.89
566,898

+0.78 (15.26%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.77 -0.12 (-2.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BDTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Black Diamond Therapeutics, Inc. [BDTX]

Reports for Purchase

Showing records 1 - 20 ( 82 total )

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

04/08/2024

Company Report

Pages: 8

Landscape Analysis Reinforces BDTX-1535 Opportunity; Raising PT to $16

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

04/08/2024

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

04/05/2024

Industry Report

Pages: 10

HEALTHCARE- The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

03/18/2024

Company Report

Pages: 5

Data Updates Expected Later this Year; 2023 Financials Reported; Modulating PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

03/13/2024

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

03/13/2024

Company Report

Pages: 6

Q4 Financials; GBM Ph1 Update in 2Q:24; BDTX-1535 Ph2 NSCLC Data in 3Q:24

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

03/06/2024

Industry Report

Pages: 14

AACR 2024 Abstract Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

01/05/2024

Company Report

Pages: 5

Expected 2024 Milestones Announced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

01/04/2024

Daily Note

Pages: 7

Green Light for First-Line NSCLC Study; Key Updates Set Up Busy 2024

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

12/13/2023

Daily Note

Pages: 5

BDTX-1535 Data Update in GBM; Remain Intrigued

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

12/13/2023

Company Report

Pages: 5

Topline GBM Data Announced For BDTX-1535; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

11/22/2023

Company Report

Pages: 5

Several Datasets Expected; 3Q23 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

11/07/2023

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

11/06/2023

Company Report

Pages: 7

Q3 Financials; GBM Update Ahead: Busy 2024

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

10/30/2023

Industry Report

Pages: 73

Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

10/17/2023

Company Report

Pages: 4

BDTX-1535 Dose Escalation NSCLC Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

10/16/2023

Daily Note

Pages: 19

EORTC-NCI-AACR 2023: Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

10/05/2023

Industry Report

Pages: 14

Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

09/12/2023

Daily Note

Pages: 7

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Black Diamond Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

09/11/2023

Daily Note

Pages: 5

BDTX-1535 Forges Ahead; Landscape Updates at WCLC

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party